About
Dana Friess obtained her Master’s degree in Experimental Biomedicine at the University of Linkoping, Sweden, in 2022. She has previously worked with zebrafish-xenograft models for the screening of nanoparticle-drug delivery, patient-derived organoid and xenograft mouse models of endometrial cancer and humanised skin graft transplantations in mice to investigate genetic skin disorders.
Dana started her PhD in the Cancer Neuroscience lab in 2023, where she has focused on the development and establishment of a novel, orthotopic quiescence tracking mouse model (QuiT model) of high-grade glioma. Her ongoing research investigates different treatment approaches targeting quiescent glioma stem cells through genetic overexpression as well as clinically-relevant compounds in combination with the standard of care.